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Introduction
Reduced-intensity conditioning (RIC) regimens emerged 15
years ago1-3 with the aim of decreasing the toxicities and mor-
bidities related to allogeneic stem cell transplantation (SCT).
Progressively the concept of RIC switched to the concept of
reduced-toxicity conditioning (RTC) regimens which are cur-
rently the majority of the conditioning regimens used world-
wide.4-5 Due to lower non-relapse mortality associated with RIC
and RTC, such regimens allow older patients or patients with
co-morbidities to be transplanted. The combination of fludara-
bine, an intermediate dose of intravenous busulfan and low-
dose antithymocyte globulins is among the most popular RIC
regimens used in Europe, particularly in France.6-9 Nevertheless,
relapse remains challenging after such regimens.6-11 Therefore,
attempts to intensify the RIC regimen without increasing non-
relapse mortality might be an attractive option in order to
obtain better disease control while waiting for the immune
graft-versus-leukemia effect. Thus, incorporation of drugs with
greater anti-tumor activity and acceptable toxicity merits fur-
ther investigation as part of RTC approaches. 
Clofarabine is a second-generation purine analog which
requires intracellular phosphorylation to be active. Clofarabine’s
triphosphate impedes DNA synthesis and repair by inhibiting
ribonucleotide reductase and DNA polymerase. It has been doc-
umented that clofarabine has significant anti-leukemic activity,
particularly in relapsed acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL), and the drug is approved
by the United States Food and Drug Administration for the
treatment of pediatric ALL patients after at least two prior regi-
mens. Hand-foot syndrome and reversible liver function abnor-
malities are the two main complications of the drug.12-14
Clofarabine combines the most favorable pharmacokinetic
properties of the first-generation purine analogs, namely flu-
darabine and cladribine, with superior anti-leukemic activity,
due to an increased resistance to deamination and phosphorol-
ysis, conferring better drug stability.12 Direct induction of apop-
tosis by activation of caspase 9 and a direct interaction with the
mitochondrial membrane may also play a role in this better
anti-leukemic effect.14 Thus, one can also exploit the anti-
leukemic, immunosuppressive effects and the favorable toxicity
profile of clofarabine in the setting of a RTC regimen prior to
allogeneic SCT. At present, experience with clofarabine-con-
taining regimens before allogeneic SCT in acute leukemia
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We prospectively evaluated the safety and efficacy of a clofarabine, intravenous busulfan and antithymocyte glob-
ulin-based reduced-toxicity conditioning (CloB2A2) regimen before allogeneic stem cell transplantation. Thirty
high-risk patients (median age: 59 years; acute myeloid leukemia n=11, acute lymphoblastic leukemia n=13;
myelodysplastic syndrome n=5, bi-phenotypic leukemia n=1) were included in this phase 2 study. At time of their
transplant, 20 and seven patients were in first and second complete remission, respectively, while three patients
with myelodysplastic syndrome were responding to chemotherapy or who had not been previously treated. The
CloB2A2 regimen consisted of clofarabine 30 mg/m²/day for 4 days, busulfan 3.2 mg/kg/day for 2 days and
antithymocyte globulin 2.5 mg/kg/day for 2 days. The median follow-up was 23 months. Engraftment occurred
in all patients. The 1-year overall survival, leukemia-free survival, relapse incidence and non-relapse mortality rates
were 63±9%, 57±9%, 40±9%, and 3.3±3%, respectively. Comparing patients with acute myeloid
leukemia/myelodysplastic syndrome versus those with acute lymphoblastic leukemia/bi-phenotypic leukemia, the
1-year overall and leukemia-free survival rates were 75±10% versus 50±13%, respectively (P=0.07) and 69±12%
versus 43±13%, respectively (P=0.08), while the 1-year relapse incidence was 25±11% versus 57±14%, respectively
(P=0.05). The CloB2A2 regimen prior to allogeneic stem cell transplantation is feasible, allowing for full engraft-
ment and low toxicity. Disease control appears to be satisfactory, especially in patients with acute myeloid
leukemia/myelodysplastic syndrome. The trial was registered at www.clinicaltrials.gov no. NCT00863148.
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ABSTRACT
patients is still scarce and mostly includes series of patients
with active disease at the time of transplantation.15-18 We
recently reported on a retrospective series of 88 AML/ALL
patients (73% with active disease at the time of their trans-
plant) receiving a clofarabine-containing RIC regimen: the 2-
year overall survival rates of these AML and ALL patients
were only 35% and 0%, respectively.18
Here we present the results of a prospective, multicenter
phase 2 trial testing the use of clofarabine as part of the con-
ditioning regimen in replacement of fludarabine, in combi-
nation with intravenous busulfan and antithymocyte globu-
lin, in 30 patients with high-risk myelodysplastic syndromes
(MDS) or acute leukemia in remission or not previously
treated at the time of transplantation.
Methods 
Study design 
This prospective phase 2 study was conducted at six transplant
centers in France (Bordeaux, Lyon, Nantes, Marseille, Strasbourg
and Paris-Saint-Louis). The study was approved by each institution-
al review board of the participating centers, the Rennes’ ethical
committee and the cellular therapy committee of the Agence
Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). Patients
eligible for a RIC allogeneic SCT, aged between 18 and 65 years old,
with high-risk MDS19 not previously treated or in response after
chemotherapy, or with high-risk AML or ALL20-22 in first or second
complete remission at transplant were considered for the purpose
of this study. Patients were not eligible for a myeloablative regimen
mainly because of age or because of their status beyond first com-
plete remission. Other eligibility criteria included a Karnofsky per-
formance status score ≥70% and a comorbidity score <3 according
to Sorror et al.23 (see Online Supplementary Material). All patients pro-
vided informed consent. Overall, 30 patients (male n=18, median
age: 59 years) were included in this prospective study between
October 2009 and August 2012. Only HLA-compatible sibling
donors (n=14) or 10 out of 10 HLA-identical matched unrelated
donors (n=16) were permitted. The characteristics of the patients
and donors are shown in Table 1. Details of the conditioning regi-
men, graft source and graft-versus-host disease (GVHD) prophylaxis
are given in Table 2. Definitions of hematopoietic reconstitution,
engraftment, chimerism and immune reconstitution are provided in
the Online Supplementary Material. Allogeneic or autologous recon-
stitution was evaluated by donor CD3+ T-cell chimerism studies as
previously described.24
Statistical analyses
The primary end-point of the trial was the assessment of
leukemia-free survival at 1 year after allogeneic SCT. An A’Hern
single-stage exact plan design was applied (see Online
Supplementary Material). Secondary end-points were overall sur-
vival, relapse incidence, non-relapse mortality, engraftment, acute
and chronic GVHD rates, percentage of donor chimerism and
immune reconstitution post-allograft. Toxicity was evaluated
according to the NCI criteria version 4. Overall survival was
defined as the time from day 0 of allogeneic SCT to death or last
follow-up for surviving patients. Leukemia-free survival was
defined as the time from day 0 of allogeneic SCT to time without
evidence of relapse or disease progression censored at the date of
death or last follow-up. Probabilities of overall and leukemia-free
survival were calculated using the Kaplan-Meier method and log-
rank test. Relapse was defined as any event related to re-occur-
rence of the disease. Non-relapse mortality was defined as death
from any cause without previous relapse or progression.
Cumulative incidence curves were used for relapse incidence and
non-relapse mortality in a competing risk setting.25 Acute and
chronic GVHD were diagnosed and graded according to standard
criteria.26,27 Death was considered as a competing event to GVHD.
The log-rank test was used for univariate comparisons and the
Gray test for cumulative incidence curves. For the purpose of this
study, the single case of bi-phenotypic leukemia was considered
as ALL for comparison of outcomes between AML/MDS and ALL
patients. Statistical analyses were performed using SPSS 19 (SPSS
Inc, Chicago, IL, USA), and R 3.0.1 (R Development Core Team,
Vienna, Austria) software packages.
Results
Engraftment, hematopoietic recovery and chimerism
Engraftment was observed in all patients (100%). The
median time for neutrophil recovery (>500/μL) was 18
(range, 14-26) days, while that for platelet recovery
(>20,000/μL) was 9 (range, 0-18) days. The median time for
the platelet count to be >50,000/μL was 12 (range, 0-23)
days. No secondary graft failure occurred. Full donor
chimerism was documented in 48% (n=11/23), 59%
(n=13/22) and 90% (n=9/10) of evaluable patients at day
+30, +90 and 1 year post-transplant, respectively.
Clofarabine conditioning for allo-SCT
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Table 1. Characteristics of the patients and donors.
Patients N=30
Gender: male 18 (60%)
Median age at transplant: years (range) 59 (20.6-64.5)
Karnofsky score at transplant:
100% 19 (63%)
90% 6 (20%)
80% 4 (13%)
Unknown 1 (4%)
Type of diseases:
Myelodysplastic syndrome 5 (17%)
Acute myeloid leukemia 11 (37%)
Acute lymphoblastic leukemia 13 (43%)*
Bi-phenotypic leukemia 1 (3%)
Status at transplant
First complete remission** 20 (67%)
Second complete remission*** 7 (23%)
MDS in response 2 (7%)
Non-treated MDS 1
Median interval between diagnosis and graft: months (range)6 (3.8-124)
Cytomegalovirus serology status: positive 11 (37%)
Donors
Sibling 14 (47%)
Matched unrelated 16 (53%)
Gender: male 20 (67%)
Median age: years (range) 44.7 (20-72.8)
Cytomegalovirus serology status: positive 11 (37%)
Graft (all peripheral blood stem cells)
Median nucleated cell dose (x108/Kg): 8.13 (0.59-18.29)
median (range)
Median CD34+ cell dose (x106/Kg): 6.68 (1.51-16.99)
median (range)
*including two patients with Philadelphia-positive ALL. **including ten AML/MDS
cases and ten ALL/bi-phenotypic cases. ***including three AML and four ALL cases.
Acute and chronic graft-versus-host disease
Grades 2, 3 and 4 acute GVHD occurred in ten, one and
one patients respectively. The cumulative incidence of
grades 2-4 acute GVHD at day +100 was 38±9%. The
cumulative incidences of chronic GVHD at 1 and 2 years
were 40±9% and 51±9%, respectively. Overall 15 patients
presented with chronic GVHD (limited n=7; extensive n=8).
The incidence of chronic GVHD was similar between
patients with related or unrelated donors (42% versus 54%;
P=0.54).
Toxicity
No unexpected events occurred after the transplants. The
1-year and 2-year non-relapse mortality incidences were
3.3±3% and 3.3±3%, respectively, as only one patient died
due to the graft procedure of acute GVHD while not in
relapse. Two reversible hand-foot syndromes occurred dur-
ing the conditioning phase despite systematic administra-
tion of steroids. With regards to infectious events, reactiva-
tion of Epstein-Barr virus and cytomegalovirus occurred in
six and five patients, respectively, while only one case of
invasive aspergillosis infection was observed. Epstein-Barr
virus-related lymphoma occurred in one patient after reacti-
vation of the virus; the patient was treated effectively with
rituximab. Bacterial sepsis was documented in eight
patients. Finally, only two reversible grade 3 hepatic events
were reported.
Outcomes (Figure 1)
With a median follow-up of 23 (range, 14-48) months
after allogeneic SCT, the 1-year overall survival, leukemia-
free survival and relapse incidence rates were 63±9%,
57±9% and 40±9%, respectively. The corresponding fig-
ures at 2 years were 58±10%, 53±9% and 43±9%, respec-
tively. At 1 year, 12 patients had relapsed (40%) within a
median time of 3.5 (range, 2.3-11.6) months after trans-
plantation. One additional relapse occurred at 13.1 months.
Eleven patients died within the first year. Overall, 14
patients died, including 13 patients already in relapse. The
causes of death were mainly relapse in 11, then GVHD in
two (including one after donor lymphocyte infusion for
relapse) and sepsis in one. 
Comparison of outcomes between patients with different
malignant conditions (Figure 2)
Compared to patients with ALL/bi-phenotypic leukemia
patients, those with MDS/AML had a higher 1-year overall
survival rate (75±10% versus 50±13%; P=0.16) and a higher
1-year leukemia-free survival rate (69±12% versus 43±13%;
P=0.15). The 1-year relapse incidence was lower (25±11%
versus 57±14%; P=0.09) among the MDS/AML group,
whereas the 1-year non-relapse mortality was not signifi-
cantly different between the two groups (MDS/AML: 6±6%
versus 0%, P=0.36). The 2-year overall and leukemia-free
survival rates remained higher for MDS/AML patients than
those for patients with ALL/bi-phenotypic leukemia
(75±10% versus 38±14%, P=0.07; and 69±12% versus
36±13%, P=0.08) while the 2-year relapse incidence was still
lower (25±11% versus 64±14%; P=0.05). Finally, the 2-year
non-relapse mortality was similar in the two groups
(MDS/AML: 6±6% versus 0%; P=0.36), as was the incidence
of chronic GVHD (MDS/AML: 38% versus 64%, P=0.14).
Immune reconstitution
A normal median count of lymphocytes was not reached
at 1 year post-transplant (median: 1110/μL range: 680-4080)
while the median monocyte count was always within the
normal range before and within the first year post-trans-
plant. All median counts increased between month +3 and
month +12: CD3+ T cells: 466/μL versus 639/μL; CD4+ T
cells: 84/μL versus 214/μL; CD8+ T cells: 386/μL versus
419/μL; CD19+ B cells: 23/μL versus 267/μL; natural killer
cells: 210/μL versus 333/μL. Normal values of natural killer
cells and CD8+ T cells were achieved as soon as day +100.
The median counts of CD3+, CD4+ T cells and CD19+ B cells
were below the normal range during the first year post-
transplant. A normal median immunoglobulin count was
not achieved at 1 year post-transplant (median: 3.6 g/L,
range: 1.7-12.2).
Discussion
This prospective phase 2 trial is the first to report the fea-
sibility, safety and efficacy of a RIC/RTC regimen, based
on clofarabine, intravenous busulfan and antithymocyte
globulins (CloB2A2), prior to allogeneic SCT. Thirty
patients with high-risk MDS or acute leukemias who were
ineligible for standard conventional myeloablative trans-
plantation, were enrolled in the study. The main differ-
ences between previous studies using clofarabine and
busulfan and ours are the fact that patients were consid-
ered prospectively and did not have active disease at the
time of transplantation. Full engraftment was observed in
all cases suggesting a sufficient immunosuppressive activi-
ty of clofarabine in combination with intermediate doses
of busulfan and anti-thymocyte globulin. Because the
study targeted a high-risk population, the choice was made
P. Chevallier et al.
1488 haematologica | 2014; 99(9)
Table 2. The “CloB2A2” RIC/RTC regimen.
Day-8 Day-7 Day-6 Day-5 Day-4 Day-3 Day-2 Day-1 Day 0
IV CLOFARABINE* x x x x
30 mg/m2/day
IV BUSULFAN
3.2 mg/kg/day x x
ANTITHYMOCYTE GLOBULIN (Thymoglobuline)
2.5 mg/kg/day x x
GVHD prophylaxis= cyclosporine alone x x x x
Graft (PBSC only)** x
RIC/RTC: redused-intensity/toxicity conditioning; IV: intravenous; GVHD: graft-versus-host disease; PBSC: peripheral blood stems cells. *Corticosteroids at a dose of 1 mg/Kg/day
were used as prophylaxis during clofarabine administration in order to prevent hand-foot syndrome. Supportive care was at the discretion of the investigators of each participating
center.
to use cyclosporine alone for GVHD prophylaxis. Our goal
was to obtain some GVHD in these high-risk patients as  a
guarantee of the graft-versus-leukemia effect and lower
relapse rate. Our objective of at least 16 patients not in
relapse at 1 year post-transplant was achieved, allowing us
to envisage a phase 3 trial in which fludarabine will be
compared to clofarabine as part of the RTC regimen.
Moreover, we were able to study some aspects of immune
reconstitution after the CloB2A2 regimen. We show here
that monocytes, T, B, and NK cells as well as gammaglob-
ulin reconstitution were similar to those that can be
observed after fludarabine-based RIC regimens.9
Furthermore, the toxicity was very low compared to other
clofarabine-based conditioning regimens which included
cytarabine15 or melphalan,16,17 with a non-relapse mortality
rate below 5% at 1 year, and only two cases of reversible
grade 3 hepatic events and no renal toxicity. This could be
explained not only by the fact that none of the patients had
active disease at the time transplantation and had not been
heavily previously treated (most cases were if first com-
plete remission), but also by the particular schedule we
used here, with the drugs being administered successively
and not concomitantly. 
Results were particularly interesting in MDS/AML cases
with 1-year overall and leukemia-free survival rates of 75%
and 69%, respectively. No relapses occurred after 1 year
post-transplant and the same survival rates were observed at
2 years. This latter fact suggests effective disease control in
such high-risk patients. Some of the largest RIC allogeneic
SCT studies for MDS/AML (including various RIC regi-
mens) had showed 2-year overall survival rates of less than
Clofarabine conditioning for allo-SCT
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Figure 1. Overall survival (A), leukemia-free survival (B), relapse inci-
dence (C) and non-relapse mortality (NRM) (D) for the whole cohort
(n=30).
Figure 2. Comparison of outcomes between MDS/AML patients
(n=16) and ALL/bi-phenotypic patients (n=14): Overall survival (A),
leukemia-free survival (B) and relapse incidence (C).
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50%.10,28 In the current study, the relatively good results in
MDS/AML are not explained by a higher incidence of
chronic GVHD occurrence after transplant which is general-
ly associated with a higher allogeneic GVL effect and higher
survival rate in patients.29 One may hypothesize that it is
rather related to the stronger anti-leukemic activity of clo-
farabine in AML itself, as suggested by the EBMT survey18
and the study by Mageneau et al.,30 in which patients with
AML with active disease at transplantation were more likely
to achieve complete remission after allogeneic SCT than
were patients with other diseases, especially ALL. Thus, it
would be interesting in the future to confirm these results in
a larger cohort and to compare the CloB2A2 regimen
prospectively to the results of other widely used fludara-
bine-based RIC regimens (e.g. fludarabine, intravenous
busulfan, antithymocyte globulin versus clofarabine, intra-
venous busulfan, antithymocyte globulin) in the particular
setting of patients with MDS/AML in order to demonstrate
its superiority. 
Despite a very low non-relapse mortality rate, results for
ALL/bi-phenotypic leukemia cases were within the range
previously published in literature for older patients, with
overall and leukemia-free survival rates of 38% and 36% at
2 years.11,31-33 In the retrospective registry-based study by
Mohty et al., which included the largest number of ALL
cases for RIC allogeneic SCT (n=127, median age 56
years),11 the 2-year overall and leukemia-free survival rates
were 48% and 32%, respectively (51% and 35% for
patients in first complete remission and 33% and 20% for
those in second complete remission). Although better
results may be obtained in younger patients,34,35 considering
the prospective aspect of the trial and the high-risk and
older population here, our results appear somewhat encour-
aging. Lymphoblasts may not be as sensitive as the malig-
nant cells in AML/MDS to clofarabine. One of the reasons
may be that, while the anti-apoptotic Bcl2 protein seems to
play a crucial role in the survival of lymphoid cells,36 Bcl2
over-expression itself confers resistance to clofarabine in the
particular setting of ALL.37 Thus, anti-Bcl2 therapy, such as
ABT-737 may overcome the resistance to clofarabine in
ALL patients,37 and should be tested as part of the condition-
ing regimen.
One possible way of improving the results of the current
CloB2A2 regimen for both myeloid and lymphoid acute
leukemia could be to increase the dose of either clofarabine
(given for 5 days rather than 4 days, for example), as is
already the case when considering induction or salvage
chemotherapy for patients with de novo or relapsed dis-
ease,12-14 or busulfan, as has been tested recently by our
group (the FB3A2 regimen),38 or of both drugs (CloB3 or
CloB4 regimens).39,40 Another way would be to administer
clofarabine and busulfan concomitantly since it has been
demonstrated that there is a synergistic effect between the
two drugs.41 Another interesting perspective is to investigate
the combination of clofarabine, fludarabine and busulfan in
patients with acute leukemia, using pharmacokinetically-
guided doses of busulfan in order to guarantee the safety of
the procedure.39,40
In conclusion, this phase 2, prospective, multicenter trial
showed that a CloB2A2 RIC/RTC regimen prior to allogene-
ic SCT in patients with high-risk MDS/leukemia is feasible,
enabling full engraftment and very low toxicity. Disease
control appeared to be satisfactory, especially in AML/MDS,
warranting a prospective comparison with other widely
used fludarabine-based RIC regimens.
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